141 related articles for article (PubMed ID: 37665685)
21. Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.
Heng JE; Raman S; Wong ZY; Beh VJN
Daru; 2024 Jun; 32(1):67-76. PubMed ID: 37903943
[TBL] [Abstract][Full Text] [Related]
22. [Costs of intravenous vs. subcutaneous administration of trastuzumab in peruvian patients with HER2-positive breast cancer - An observational analysis of direct and indirect costs].
Olivera Changra H; Robles Díaz JF
J Healthc Qual Res; 2022; 37(3):147-154. PubMed ID: 34887227
[TBL] [Abstract][Full Text] [Related]
23. Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2017; 17(16):1-86. PubMed ID: 31210833
[TBL] [Abstract][Full Text] [Related]
24. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study.
Fallowfield L; Osborne S; Langridge C; Monson K; Kilkerr J; Jenkins V
Breast; 2015 Apr; 24(2):166-70. PubMed ID: 25623753
[TBL] [Abstract][Full Text] [Related]
25. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
Harvey MJ; Zhong Y; Morris E; Beverage JN; Epstein RS; Chawla AJ
PLoS One; 2022; 17(1):e0261336. PubMed ID: 35073335
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study.
van Deen WK; Khalil C; Bonthala NN; Gale R; Patel DB; Warui E; Melmed GY; Spiegel BMR
Dig Dis; 2023; 41(3):412-421. PubMed ID: 36476714
[TBL] [Abstract][Full Text] [Related]
27. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
28. Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients.
Delgado Sánchez O; Gutiérrez A; do Pazo F; Ginés J; Martorell C; Boyeras B; Bento L; Garcia-Recio M; Sampol A
Clinicoecon Outcomes Res; 2019; 11():695-701. PubMed ID: 31819561
[TBL] [Abstract][Full Text] [Related]
29. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Ciruelos EM; Montaño A; Rodríguez CA; González-Flores E; Lluch A; Garrigós L; Quiroga V; Antón A; Malón D; Chacón JI; Velasco M; Gonzalez-Cortijo L; Jolis L; Echarri MJ; Muñoz M; Pascual T; Amigo Y; Casas M; Carrasco E; Casas A
Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13253. PubMed ID: 32578279
[TBL] [Abstract][Full Text] [Related]
30. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
North RT; Harvey VJ; Cox LC; Ryan SN
Clinicoecon Outcomes Res; 2015; 7():423-30. PubMed ID: 26251623
[TBL] [Abstract][Full Text] [Related]
31. Update on the subcutaneous administration of rituximab in Canadian cancer centres.
Stewart D; Aucoin JS; Crosbie T; Forman M; Lye E; Christofides A; Mitha A
Curr Oncol; 2020 Apr; 27(2):113-116. PubMed ID: 32489254
[TBL] [Abstract][Full Text] [Related]
32. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S; Ammendolea C; Christofides A; Edwards S; Incekol D; Pourmirza B; Kfoury S; Poirier B
Curr Oncol; 2019 Feb; 26(1):e70-e80. PubMed ID: 30853812
[TBL] [Abstract][Full Text] [Related]
33. Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review.
Overton PM; Shalet N; Somers F; Allen JA
Patient Prefer Adherence; 2021; 15():811-834. PubMed ID: 33907384
[TBL] [Abstract][Full Text] [Related]
34. The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home.
Tjalma W; Huizing MT; Papadimitriou K
Facts Views Vis Obgyn; 2017 Mar; 9(1):51-55. PubMed ID: 28721185
[TBL] [Abstract][Full Text] [Related]
35. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
[TBL] [Abstract][Full Text] [Related]
36. Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.
Drill E; Qiu A; Shapouri S; To TM; Ravelo A; Schade J; Dawson K; Matasar M
Oncology (Williston Park); 2021 Dec; 35(12):804-811. PubMed ID: 35089000
[TBL] [Abstract][Full Text] [Related]
37. [Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)].
Favier M; Le Goc-Sager F; Vincent-Cantini I; Launay V; Giroux EA; Lièvremont K; Bonnet I; Barbe C; Duval E; Loric N; Delbaldo C
Bull Cancer; 2018 Oct; 105(10):862-872. PubMed ID: 30244982
[TBL] [Abstract][Full Text] [Related]
38. Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
De Cock E; Kritikou P; Sandoval M; Tao S; Wiesner C; Carella AM; Ngoh C; Waterboer T
PLoS One; 2016; 11(6):e0157957. PubMed ID: 27362533
[TBL] [Abstract][Full Text] [Related]
39. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A; Avivi I; Bittner B; Bouabdallah R; Brewster M; Catalani O; Follows G; Haynes A; Hourcade-Potelleret F; Janikova A; Larouche JF; McIntyre C; Pedersen M; Pereira J; Sayyed P; Shpilberg O; Tumyan G
J Clin Oncol; 2014 Jun; 32(17):1782-91. PubMed ID: 24821885
[TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting.
Barat EC; Arrii MLE; Soubieux-Bourbon A; Daouphars M; Varin R; Tilleul PR
Breast; 2023 Dec; 72():103588. PubMed ID: 37857129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
